Author: PharmaSignal News Desk

Novo Nordisk is set to reveal results of its semaglutide study for Alzheimer’s, potentially expanding its indications.

Novo Nordisk Ozempic discount at $199 boosts telehealth partnerships, increasing drug access and sales.

RFK Jr. profile reveals insights into his health policy stance, impacting millions of Americans.

Moderna $1.5B investment aims to expand its vaccine franchise and achieve breakeven by 2028.

Purdue Pharma settlement approved, Sacklers to pay $7 billion over 15 years to address opioid crisis.

Regeneron Eylea HD approvals enhance its market position with two new indications, intensifying competition with Roche’s Vabysmo.

Sarepta FDA warning highlights heart risk in Elevidys therapy, affecting Duchenne muscular dystrophy patients.

Vaccine reformulation proposals could significantly impact manufacturers and access in over 50 countries.

Vaccine Ingredient Ban could impact U.S. childhood vaccine schedule and require costly reformulations.

HIV prevention drug distribution begins in Zambia and Eswatini with 1,000 doses, excluding South Africa.